Join our daily newsletter At The Bell to receive exclusive market insights
- Cynata Therapeutics (CYP) receives notice of allowance for a patent application covering its Cymerus mesenchymal stem cell (MSC) platform technology
- A notice of allowance is sent to an applicant when the United States Patent and Trademark Office intends to issue a patent
- The patent will be wholly owned by Cynata and describes a method for ensuring quality and purity of Cynata’s finished therapeutic MSC products
- Cynata says it anticipates the granting of the patent to occur in February, with an expiration date of 15 November, 2037
- Cynata Therapeutics last traded at 30 cents at 1:10 pm AEDT
Cynata Therapeutics (CYP) has received notice of allowance for a patent application covering its Cymerus mesenchymal stem cell (MSC) platform technology.
The company received the notice from the United States Patent and Trademark Office (USPTO) for the patent entitled “Pluripotent Stem Cell Assay”.
The patent will be wholly owned by Cynata and describes a method for ensuring quality and purity of Cynata’s finished therapeutic MSC products.
A notice of allowance is sent to an applicant when the USPTO intends to issue a patent.
The patent adds to the existing broad and comprehensive IP protection of the Cymerus manufacturing platform and its unique ability to yield highly consistent MSCs at scale, from a single donation. This will then be used to create therapeutic stem cell products.
Cynata Chief Operating Officer Dr Kilian Kelly said the company is delighted its product development activities have resulted in another patent.
“This important achievement adds to our portfolio of wholly-Cynata owned patents and patent applications, providing further protection over our proprietary Cymerus technology to 2037 and beyond,” Dr Kelly said.
“The novel method described in the patent specification and patent claims enhances our competitive position around the Cymerus platform which enables the production of consistent, high-quality mesenchymal stem cells at scale.
“These important characteristics afford a major competitive advantage in the ongoing development of off-the-shelf therapeutic stem cell products to target a range of devastating diseases worldwide.”
Cynata said it anticipates the granting of the patent to occur in February, with an expiration date of 15 November, 2037.
Cynata Therapeutics last traded at 30 cents at 1:10 pm AEDT.
